Bonney was the president and chief executive officer of Cubist Pharmaceuticals, from 2003 until his retirement in 2014 coinciding with the company being acquired by Merck & Co. for $9.5 billion.

[1] Bonney, a native of the Greater Boston area, graduated from Bates College before entering the pharmaceutical industry.

[2] Bonney serves as an advisor to former Prime Minister David Cameron's Commission on Antimicrobial Resistance (AMR).

[4] Bonney began his formal business career after graduating from Bates in 1984 in small pharmaceutical startups, before leaving the companies in various sales management positions.

At the company, "he built the commercial infrastructure for the launch of Avonex, an injectable biologic therapy for the treatment of multiple sclerosis.

He held various positions in sales, marketing and strategic planning at Zeneca Pharmaceuticals, ending his eleven-year career and served as its National Business Director.

[2] In many media profiles, his first days at Cubist received mixed profit levels and failed to reach the same financial success as his work at Biogen.

[2] Shortly after his award, Cubist appeared on Fortune 2010's List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500.

[15] Bonney left the company as CEO tracked to reach $2 billion in sales and to expand the revenue stream of its flagship drug Cubicin.

[3] His position encompassed guiding start up companies to financial viability and encourage marketplace completion in the field of bio medicine.

[19] Upon his retirement Bonney was appointed to numerous boards including NPS Pharmaceuticals, Inc. in which he served as Director from January 2005 to February 21, 2015.